^
Association details:
| Biomarker: | PIK3CA mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
Excerpt:
...- gastric tumors carrying PIK3CA mutation or amplification, or HER2-overexpression, or both;...
Trial ID:
Source:
Title:
C074 - Preclinical study of antitumor effect of alpelisib combined with paclitaxel in gastric caner
Published date:
10/29/2019
Excerpt:
These three PIK3CA mutant cells were predominantly sensitive to alpelisib...Alpelisib alone or in combination with paclitaxel demonstrated promising anti-tumor activity and tolerability in in vitro and in vivo models of PIK3CA mutant GC via inactivating PI3K down-stream molecules...
Source:
Title:
C074 - Preclinical study of antitumor effect of alpelisib combined with paclitaxel in gastric caner
Published date:
10/29/2019
Excerpt:
These three PIK3CA mutant cells were predominantly sensitive to alpelisib...Alpelisib alone or in combination with paclitaxel demonstrated promising anti-tumor activity and tolerability in in vitro and in vivo models of PIK3CA mutant GC via inactivating PI3K down-stream molecules...
Source:
Title:
Characterization of the Novel and Specific PI3Ka Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Excerpt:
Most of the tumor models that carried a PIK3CA mutation or amplification responded to NVP-BYL719 (response defined as T/C < 20%). In contrast, in most of the tumor models that carried a PTEN mutation or were PIK3CA wild type, we observed progressive disease.
DOI:
10.1158/1535-7163.MCT-13-0865
